Skip to content

Editors

Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

U.S., China enforcement crossfire creates new risks

At the beginning of this year, China’s president Xi Jinping promised to fight both “tigers” and “flies” — high-ranking and low-ranking corrupt officials — in his crackdown on corruption. Since then, the anti-graft campaign has led to the conviction of Bo Xilai and to the front-page investigations of foreign companies in the pharmaceutical and oil and gas sectors, among others.… Continue Reading

Drug sellers ‘take vacations’ amid China anti-graft campaign

Pharmas have told their sales teams to halt all activity in China to avoid being caught in the nationwide “enforcement storm,” according to the Guangdong-based Yangcheng Evening News.

“It is rumored that police in plain clothes are patrolling in hospitals; drug sales representatives will be fined 500 yuan ($81) and regional sales managers 1000 yuan ($162) once being caught in hospitals,” an unidentified sales representative told the paper.Continue Reading

GSK In China: A Game Changer in Compliance

The entry of the Chinese government into the international fight against corruption and bribery is truly a game-changer. While there may be many reasons for this very public move by the Chinese government, it is clear that foreign companies are now on notice.… Continue Reading

Can we relax yet?

Professor Peter J. Henning of Wayne State University Law School (Photo courtesy of Wayne Law)Over the last decade, since the passage of the Sarbanes-Oxley Act in 2002, publicly traded corporations have poured significant resources into their compliance programs to prevent wrongdoing, or to at least be an early warning system for what might become a problem.… Continue Reading

With flashy pharma sweep, China steps into global enforcement role

Here’s a thoughtful comment from a U.S.-based compliance professional who asked not to be named:

                    *     *     *

I think that as China continues to march to the largest economy in the world it is going to have increasing influence in the world in many areas.… Continue Reading